FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946005791> ?p ?o ?g. }

• W2946005791 endingPage "809" @default.
• W2946005791 startingPage "798" @default.
• W2946005791 abstract "Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestinal tract. Sodium zirconium cyclosilicate-associated restoration and maintenance of normokalemia and adverse events were evaluated in a two-part, open label, phase 3 trial.In the correction phase, adult outpatients with plasma potassium ≥5.1 mmol/L (i-STAT Point-of-Care) received sodium zirconium cyclosilicate 10 g three times daily for 24-72 hours until normokalemic (potassium =3.5-5.0 mmol/L). Qualifying participants entered the ≤12-month maintenance phase and received sodium zirconium cyclosilicate 5 g once daily titrated to maintain normokalemia without dietary or medication restrictions. Prespecified primary end points were restoration of normal serum potassium values (3.5-5.0 mmol/L) during the correction phase and maintenance of serum potassium ≤5.1 mmol/L during the maintenance phase. Adverse events were assessed throughout.Of 751 participants, 746 (99%) achieved normokalemia during the correction phase (mean serum potassium =4.8 mmol/L; 95% confidence interval, 4.7 to 4.8) and entered the maintenance phase; 466 (63%) participants completed the 12-month trial. Participants were predominantly white, men, and age ≥65 years old; 74% had an eGFR<60 ml/min per 1.73 m2, and 65% used renin-angiotensin-aldosterone system inhibitors. Mean time on sodium zirconium cyclosilicate was 286 days. Mean daily sodium zirconium cyclosilicate dose was 7.2 g (SD=2.6). Over months 3-12, mean serum potassium was 4.7 mmol/L (95% confidence interval, 4.6 to 4.7); mean serum potassium values ≤5.1 and ≤5.5 mmol/L were achieved by 88% and 99% of participants, respectively. Of 483 renin-angiotensin-aldosterone system inhibitor users at baseline, 87% continued or had their dose increased; 11% discontinued. Among 263 renin-angiotensin-aldosterone system inhibitor-naïve participants, 14% initiated renin-angiotensin-aldosterone system inhibitor therapy. Overall, 489 (66%) participants experienced adverse events during the maintenance phase, and 22% experienced a serious adverse event. Of eight (1%) deaths, none were considered related to sodium zirconium cyclosilicate. Nine (1%) and 34 (5%) participants experienced serum potassium <3.0 and 3.0-3.4 mmol/L, respectively.After achieving normokalemia, individualized once daily sodium zirconium cyclosilicate was associated with maintenance of normokalemia without substantial renin-angiotensin-aldosterone system inhibitor changes for ≤12 months." @default.
• W2946005791 created "2019-05-29" @default.
• W2946005791 creator A5001846180 @default.
• W2946005791 creator A5005504016 @default.
• W2946005791 creator A5008382551 @default.
• W2946005791 creator A5008586613 @default.
• W2946005791 creator A5016502106 @default.
• W2946005791 creator A5021193745 @default.
• W2946005791 creator A5022314919 @default.
• W2946005791 creator A5042553930 @default.
• W2946005791 creator A5046497650 @default.
• W2946005791 creator A5052533254 @default.
• W2946005791 creator A5054404109 @default.
• W2946005791 creator A5057084111 @default.
• W2946005791 creator A5068654431 @default.
• W2946005791 creator A5070167982 @default.
• W2946005791 date "2019-05-20" @default.
• W2946005791 modified "2023-10-16" @default.
• W2946005791 title "Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia" @default.
• W2946005791 cites W122788210 @default.
• W2946005791 cites W1596584892 @default.
• W2946005791 cites W1993617109 @default.
• W2946005791 cites W2008452717 @default.
• W2946005791 cites W2030933332 @default.
• W2946005791 cites W2038398324 @default.
• W2946005791 cites W2041162893 @default.
• W2946005791 cites W2046440136 @default.
• W2946005791 cites W2100169278 @default.
• W2946005791 cites W2100987099 @default.
• W2946005791 cites W2101879409 @default.
• W2946005791 cites W2152271789 @default.
• W2946005791 cites W2156753852 @default.
• W2946005791 cites W2168582599 @default.
• W2946005791 cites W2219432653 @default.
• W2946005791 cites W2319308197 @default.
• W2946005791 cites W2324948948 @default.
• W2946005791 cites W2397278962 @default.
• W2946005791 cites W2523804795 @default.
• W2946005791 cites W2603110444 @default.
• W2946005791 cites W2764108010 @default.
• W2946005791 cites W2772387421 @default.
• W2946005791 cites W753295172 @default.
• W2946005791 cites W917264698 @default.
• W2946005791 doi "https://doi.org/10.2215/cjn.12651018" @default.
• W2946005791 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6556727" @default.
• W2946005791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31110051" @default.
• W2946005791 hasPublicationYear "2019" @default.
• W2946005791 type Work @default.
• W2946005791 sameAs 2946005791 @default.
• W2946005791 citedByCount "109" @default.
• W2946005791 countsByYear W29460057912019 @default.
• W2946005791 countsByYear W29460057912020 @default.
• W2946005791 countsByYear W29460057912021 @default.
• W2946005791 countsByYear W29460057912022 @default.
• W2946005791 countsByYear W29460057912023 @default.
• W2946005791 crossrefType "journal-article" @default.
• W2946005791 hasAuthorship W2946005791A5001846180 @default.
• W2946005791 hasAuthorship W2946005791A5005504016 @default.
• W2946005791 hasAuthorship W2946005791A5008382551 @default.
• W2946005791 hasAuthorship W2946005791A5008586613 @default.
• W2946005791 hasAuthorship W2946005791A5016502106 @default.
• W2946005791 hasAuthorship W2946005791A5021193745 @default.
• W2946005791 hasAuthorship W2946005791A5022314919 @default.
• W2946005791 hasAuthorship W2946005791A5042553930 @default.
• W2946005791 hasAuthorship W2946005791A5046497650 @default.
• W2946005791 hasAuthorship W2946005791A5052533254 @default.
• W2946005791 hasAuthorship W2946005791A5054404109 @default.
• W2946005791 hasAuthorship W2946005791A5057084111 @default.
• W2946005791 hasAuthorship W2946005791A5068654431 @default.
• W2946005791 hasAuthorship W2946005791A5070167982 @default.
• W2946005791 hasBestOaLocation W29460057911 @default.
• W2946005791 hasConcept C126322002 @default.
• W2946005791 hasConcept C138976137 @default.
• W2946005791 hasConcept C141071460 @default.
• W2946005791 hasConcept C178790620 @default.
• W2946005791 hasConcept C179104552 @default.
• W2946005791 hasConcept C185592680 @default.
• W2946005791 hasConcept C197934379 @default.
• W2946005791 hasConcept C198710026 @default.
• W2946005791 hasConcept C2778525890 @default.
• W2946005791 hasConcept C2780243291 @default.
• W2946005791 hasConcept C42219234 @default.
• W2946005791 hasConcept C44249647 @default.
• W2946005791 hasConcept C517785266 @default.
• W2946005791 hasConcept C534791751 @default.
• W2946005791 hasConcept C537181965 @default.
• W2946005791 hasConcept C71924100 @default.
• W2946005791 hasConcept C84393581 @default.
• W2946005791 hasConcept C90924648 @default.
• W2946005791 hasConceptScore W2946005791C126322002 @default.
• W2946005791 hasConceptScore W2946005791C138976137 @default.
• W2946005791 hasConceptScore W2946005791C141071460 @default.
• W2946005791 hasConceptScore W2946005791C178790620 @default.
• W2946005791 hasConceptScore W2946005791C179104552 @default.
• W2946005791 hasConceptScore W2946005791C185592680 @default.
• W2946005791 hasConceptScore W2946005791C197934379 @default.
• W2946005791 hasConceptScore W2946005791C198710026 @default.
• W2946005791 hasConceptScore W2946005791C2778525890 @default.

• next